BOSTON, Aug. 04, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the Company is scheduled to present a corporate overview at the Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 11, 2015 at 1:20 p.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the EPIRUS’ website at http://ir.epirusbiopharma.com/events.cfm. The webcast will be archived on the Company’s website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on building a pure-play, sustainable, profitable biosimilar business. As such, EPIRUS will be able to improve patient access to important, cost-effective medicines worldwide. EPIRUS' current pipeline of biosimilar product candidates includes BOW015 (infliximab, reference biologic Remicade®), BOW050 (adalimumab, reference biologic Humira®) and BOW070 (tocilizumab, reference biologic Actemra®)i. The reference products for these candidates together generated $23 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has developed distinct strategies to penetrate the global market, leveraging partnerships to optimize value retention over the long-term. For more information visit EPIRUS’ website at www.epirusbiopharma.com.
i Remicade is a registered trademark of J&J (www.jnj.com); Humira is a registered trademark of AbbVie (www.abbvie.com); ACTEMRA is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com)